ENLIVEN THERAPEUTICS, INC. Stock-Based Compensation
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Stock-Based Compensation of $21.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $13.91M, a 80.15% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $7.40M, a 8.80% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $12.31M, a 130.59% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $7.18M, a 38.81% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $34.02M, a 68.63% increase from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $20.17M, a 56.22% increase from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $12.91M, a 304.70% increase from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $3.19M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $13.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $21.31M 10-Q · filed 2026-08-05 | $33.62M derived: sum of 3 quarters · filed 2026-08-05 | $40.81M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $7.40M 10-Q · filed 2026-05-07 | $19.71M derived: sum of 2 quarters · filed 2026-05-07 | $26.89M derived: sum of 3 quarters · filed 2026-05-07 | $34.62M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $12.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $19.50M derived: sum of 2 quarters · filed 2026-03-03 | $27.22M derived: sum of 3 quarters · filed 2026-08-05 | $34.02M 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | $7.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $14.91M derived: sum of 2 quarters · filed 2026-08-05 | $21.71M 10-Q · filed 2025-11-12 | $27.05M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $7.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $14.52M 10-Q · filed 2026-08-05 | $19.86M derived: sum of 3 quarters · filed 2026-08-05 | $25.04M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $6.80M 10-Q · filed 2026-05-07 | $12.14M derived: sum of 2 quarters · filed 2026-05-07 | $17.31M derived: sum of 3 quarters · filed 2026-05-07 | $22.46M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $5.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $10.52M derived: sum of 2 quarters · filed 2026-03-03 | $15.66M derived: sum of 3 quarters · filed 2026-03-03 | $20.17M 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | $5.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $10.32M derived: sum of 2 quarters · filed 2025-11-12 | $14.84M 10-Q · filed 2025-11-12 | $17.89M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $5.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $9.66M 10-Q · filed 2025-08-13 | $12.71M derived: sum of 3 quarters · filed 2025-08-13 | $16.12M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $4.51M 10-Q · filed 2025-05-14 | $7.57M derived: sum of 2 quarters · filed 2025-05-14 | $10.97M derived: sum of 3 quarters · filed 2025-05-14 | $15.17M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $6.46M derived: sum of 2 quarters · filed 2025-03-13 | $10.65M derived: sum of 3 quarters · filed 2025-03-13 | $12.91M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $7.60M derived: sum of 2 quarters · filed 2024-11-13 | $9.86M 10-Q · filed 2024-11-13 | $10.59M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $6.46M 10-Q · filed 2024-08-13 | $7.19M derived: sum of 3 quarters · filed 2024-08-13 | $8.29M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $2.26M 10-Q · filed 2024-05-14 | $3.00M derived: sum of 2 quarters · filed 2024-05-14 | $4.10M derived: sum of 3 quarters · filed 2024-05-14 | $4.80M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $735.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.84M derived: sum of 2 quarters · filed 2024-03-14 | $2.54M derived: sum of 3 quarters · filed 2024-03-14 | $3.19M 10-K · filed 2024-03-14 | $2.60M 10-K · filed 2023-02-10 | |||
| 2022-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.80M derived: sum of 2 quarters · filed 2023-11-09 | $2.46M 10-Q · filed 2023-11-09 | $1.94M 10-Q · filed 2022-10-25 | $1.51M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $701.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.35M 10-Q · filed 2023-08-10 | $1.44M 10-Q · filed 2022-08-03 | $412.00K derived: sum of 3 quarters · filed 2023-08-10 | $1.42M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $654.00K 10-Q · filed 2023-05-11 | $1.06M 10-Q · filed 2022-05-06 | -$289.00K derived: sum of 2 quarters · filed 2023-06-23 | $714.00K derived: sum of 3 quarters · filed 2023-06-23 | $1.63M derived: sum of 4 quarters · filed 2023-06-23 | |||
| 2021-12-31 | -$943.00K derived: 8-K 12 month − 10-Q 9 month · filed 2023-06-23 | $60.00K derived: sum of 2 quarters · filed 2023-06-23 | $977.00K derived: sum of 3 quarters · filed 2023-06-23 | $1.92M 8-K · filed 2023-06-23 | $3.85M 10-K · filed 2022-03-15 | |||
| 2021-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $1.92M derived: sum of 2 quarters · filed 2022-10-25 | $2.87M 10-Q · filed 2022-10-25 | $3.55M derived: sum of 4 quarters · filed 2022-10-25 | ||||
| 2021-06-30 | $917.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $1.86M 10-Q · filed 2022-08-03 | $2.54M derived: sum of 3 quarters · filed 2022-08-03 | $3.19M derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | $947.00K 10-Q · filed 2022-05-06 | $1.63M derived: sum of 2 quarters · filed 2022-05-06 | $2.27M derived: sum of 3 quarters · filed 2022-05-06 | $2.82M derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $679.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $1.32M derived: sum of 2 quarters · filed 2022-03-15 | $1.87M derived: sum of 3 quarters · filed 2022-03-15 | $2.23M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $642.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.19M derived: sum of 2 quarters · filed 2021-11-09 | $1.55M 10-Q · filed 2021-11-09 | $1.85M derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | $550.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $910.00K 10-Q · filed 2021-08-06 | $1.21M derived: sum of 3 quarters · filed 2021-08-06 | $1.52M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | $360.00K 10-Q · filed 2021-05-11 | $657.00K derived: sum of 2 quarters · filed 2021-05-11 | $967.00K derived: sum of 3 quarters · filed 2021-05-11 | $1.16M derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | $297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $607.00K derived: sum of 2 quarters · filed 2021-03-05 | $804.00K derived: sum of 3 quarters · filed 2021-03-05 | $899.00K 10-K · filed 2021-03-05 | ||||
| 2019-09-30 | $310.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $507.00K derived: sum of 2 quarters · filed 2020-11-05 | $602.00K 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $292.00K 10-Q · filed 2020-08-14 | ||||||
| 2019-03-31 | $95.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |